In the past few decades, the role of PPARγ and SERBP-1c in the regulation of obesity and adipocyte differentiation has been highlighted and, hence, PPARγ agonists and antagonists of synthetic or herbal origin have gained wide commercial popularity as therapeutic agents [31]. Here, PPARG is linked to obesity disorder.